Gavreto (pralsetinib) — Medica

Initial criteria

• Patient is age ≥ 12 years
• Patient has unresectable, recurrent, or metastatic disease
• Patient has rearranged during transfection (RET) fusion-positive or RET-mutation-positive disease
• The disease requires treatment with systemic therapy
• EITHER the patient has papillary or follicular thyroid carcinoma that is radioactive iodine-refractory OR the patient has oncocytic (formerly Hürthle cell) carcinoma

Approval duration

1 year